Your browser doesn't support javascript.
loading
Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort.
Vatn, Simen Svendsen; Lindstrøm, Jonas Christoffer; Moen, Aina E F; Brackmann, Stephan; Tannæs, Tone M; Olbjørn, Christine; Bergemalm, Daniel; Keita, Åsa V; Gomollon, Fernando; Detlie, Trond Espen; Lüders, Torben; Kalla, Rahul; Adams, Alex; Satsangi, Jack; Jahnsen, Jørgen; Vatn, Morten H; Halfvarson, Jonas; Ricanek, Petr; Nilsen, Hilde.
Afiliação
  • Vatn SS; Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Lindstrøm JC; Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Moen AEF; Health Services Research Unit (HØKH), Akershus University Hospital, Lørenskog, Norway.
  • Brackmann S; Department of Methods Development and Analytics, Division of Infectious Disease Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Tannæs TM; Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Olbjørn C; Department of Methods Development and Analytics, Division of Infectious Disease Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Bergemalm D; Section for Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.
  • Keita ÅV; Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Gomollon F; Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Detlie TE; Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Lüders T; Section for Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.
  • Kalla R; Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Adams A; Department of Pediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Satsangi J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Jahnsen J; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
  • Vatn MH; Digestive Diseases Unit, IIS Aragón, Zaragoza, Spain.
  • Halfvarson J; Department of Clinical Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Ricanek P; Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Nilsen H; Section for Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.
Clin Exp Gastroenterol ; 15: 5-25, 2022.
Article em En | MEDLINE | ID: mdl-35185343
BACKGROUND: Studies of the mucosal transcriptomic landscape have given new insight into the pathogenesis of inflammatory bowel disease (IBD). Recently, the predictive biomarker potential of gene expression signatures has been explored. To further investigate the mucosal gene expression in IBD, we recruited a cohort of treatment naïve patients and compared them to both symptomatic and healthy controls. METHODS: Altogether, 323 subjects were included: Crohn's disease (N = 75), ulcerative colitis (N = 87) and IBD unclassified (N = 3). Additionally, there were two control groups: symptomatic controls (N = 131) and healthy controls (N = 27). Mucosal biopsies were collected during ileocolonoscopy and gene expression in inflamed and non-inflamed mucosa was explored. Gene expression profiling was performed using Agilent G3 Human Gene Expression 860K v3 One-Color microarray. We recorded information about treatment escalation to anti-TNF agents or surgery, and anti-TNF response, to explore predictive opportunities of the mucosal transcriptome. RESULTS: Gene expression profiles in symptomatic controls in whom IBD had been excluded resembled that of IBD patients and diverged from that of healthy controls. In non-inflamed Crohn's disease and ulcerative colitis, gene set enrichment analysis revealed dysregulation of pathways involved in basic cellular biological processes. Mitochondria-associated pathways were dysregulated both in non-inflamed and inflamed Crohn's disease and ulcerative colitis (>2.6 normalized enrichment scores <-1.8). Gene expression signatures of Crohn's disease and ulcerative colitis did not predict time for treatment escalation (p = 0.175). No significant association was found between gene expression signatures and anti-TNF response. CONCLUSION: Non-inflamed samples are probably superior to inflamed samples when exploring gene expression signatures in IBD and might reveal underlying mechanisms central for disease initiation. The gene expression signatures of the control groups were related to if they were symptomatic or not, which may have important implications for future study designs.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article